Article

Continuation of study urged for diabetic macular edema insert

After completing its review of safety and efficacy data currently available, an independent data safety monitoring board once again has recommended that two pivotal phase III clinical trials, known collectively as the Fluocinolone Acetonide in Diabetic Macular Edema Study, continue under the current protocol, without change.

Alpharetta, GA-After completing its review of safety and efficacy data currently available, an independent data safety monitoring board once again has recommended that two pivotal phase III clinical trials, known collectively as the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Study, continue under the current protocol, without change. This news is according to a prepared statement issued by Alimera Sciences, which has a majority stake in the development of the proprietary intravitreal insert with fluocinolone acetonide (Medidur FA) being investigated in the trial as a treatment for diabetic macular edema (DME).

The two, duplicate, double-masked, randomized, multicenter trials of the study are following 956 patients in the United States, Canada, Europe, and India for 36 months in support of a planned global registration filing, with safety and efficacy assessed after 2 years of follow-up. Enrollment was completed in October.

"As of this latest [board] review, we continue to be on track for regulatory submissions in early 2010," said Dan Myers, Alimera's chief executive officer.

The FAME board, a group of four ophthalmologists and a biostatistician, reviewed the phase III clinical trial data. The monitoring board's charter stipulates that it perform a formal review every 6 months in addition to conducting the group's ongoing review of the trial.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.